PCG
78
-7
THC
55
-7
FLR
38
-4
STT
42
-6
RSG
59
-6
EIX
74
-4
MU
22
-6
NTRS
32
-12
TXN
33
-3
QRVO
29
-18
WMB
55
-4
SCHW
42
-4
CPB
65
11
FLS
48
-5
VRSK
61
-5
SLB
39
-3
PH
62
-2
SE
55
-3
ADSK
57
-4
FDX
37
-3
PCG
78
-7
THC
55
-7
FLR
38
-4
STT
42
-6
RSG
59
-6
EIX
74
-4
MU
22
-6
NTRS
32
-12
TXN
33
-3
QRVO
29
-18
WMB
55
-4
SCHW
42
-4
CPB
65
11
FLS
48
-5
VRSK
61
-5
SLB
39
-3
PH
62
-2
SE
55
-3
ADSK
57
-4
FDX
37
-3
Financhill
Back

Beam Therapeutics Quote, Financials, Valuation and Earnings

The Biggest Financial Event of 2024?

Click here to find out.
Sell
18

BEAM
Beam Therapeutics

Last Price:
23.25
Seasonality Move:
23.47%

7 Day Trial

ALL ACCESS PASS

$ 7

1-day winners in this choppy market

Get the 1-day winners strategy here.

Beam Therapeutics Price Quote

$23.25
-0.05 (-3.89%)
(Updated: September 7, 2024 at 6:22 AM ET)

Beam Therapeutics Key Stats

Sell
18
Beam Therapeutics (BEAM) is a Sell
Day range:
$23.07 - $24.58
52-week range:
$16.95 - $49.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
5.35
P/B ratio:
2.25%
Volume:
385.9K
Avg. volume:
803.3K
1-year change:
-5.52%
Market cap:
$1.9B
Revenue:
$377.7M
EPS:
$-1.81

How Much Does Beam Therapeutics Make?

Is Beam Therapeutics Growing As A Company?

  • What Is Beam Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.41%
  • What Is Beam Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Beam Therapeutics Stock Price Performance

What Is Beam Therapeutics 52-Week High & Low?

Beam Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Beam Therapeutics?

  • How Much Debt Does Beam Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Beam Therapeutics Have?
    Cash and short term investments quarterly total is $1B
  • What Is Beam Therapeutics’s Book Value Per Share?
    Book value per share is 10.37

Is Beam Therapeutics Cash Flow Positive?

  • What Is BEAM Cash Flow From Operations?
    Cash flow from operations (TTM) is -$137.5M
  • What Is Beam Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $73.5M
  • What Is Beam Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $121.9M

Beam Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    BEAM return on invested capital is -16.48%
  • What Is Beam Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -10.63%
  • What Is BEAM Return On Equity?
    ROE is a measure of profitability and is -16.48%

Beam Therapeutics Earnings Date & Stock Price

Beam Therapeutics Competitors

  • Who Are Beam Therapeutics's Competitors?
    Below is a list of companies who compete with Beam Therapeutics or are related in some way:
    • Perspective Therapeutics Inc (CATX)
    • Electromed Inc (ELMD)
    • Myomo Inc (MYO)
    • Intellia Therapeutics Inc (NTLA)
    • Xtant Medical Holdings Inc (XTNT)

Beam Therapeutics Dividend Yield

Beam Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0.73%
Revenue: -41.48% -9.77%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 7
Sell Recommendations: 0
Price Target: 50.14
Upside from Last Price: 115.21%

Major Shareholders

  • How many BEAM shares are owned by institutional investors?
    113.8M BEAM shares are owned by institutional investors
  • How many BEAM shares are owned by insiders?
    1.5M BEAM shares are owned by insiders